ContraFect Corporation (CFRX) News

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage...

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage...

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage...

Form PRE 14A - Other preliminary proxy statements

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage...